SUMMARY When fresh rabbit aorta is incubated with plasma, prostacyclin, a potent inhibitor of platelet aggregation, is normally released. Plasma obtained from 2 patients with systemic lupus erythematosus (SLE) inhibited prostacyclin activity, while plasma from 22 other patients with SLE and 40 normal control subjects showed normal activity. Absence of prostacyclin activity did not appear to correlate with the clinical severity of the underlying disease. The possible association of this finding and the presence of thrombotic lesions in both patients is discussed.
The incidence of thrombotic lesions in patients with systemic lupus erythematosus (SLE) is well documented and is considerably higher than that found in the general population.'2 The aetiology of these episodes is unknown.
It has recently been demonstrated that blood vessels produce prostacyclin (PGI2), an unstable product of prostaglandin endoperoxides.3 PGI2 is a potent inhibitor of platelet aggregation and may be responsible for the lack of adhesion and aggregation of platelets to intact vascular endothelial surfaces. 4 prednisone and plasma exchange. At the time of the present study she was in clinical remission, though high levels of plasma DNA binding activity and circulating immune complexes were present. She was taking prednisone 15 mg daily and azathioprine 100 mg daily. Inhibition of PGI2 activity following incubation of the patient's plasma with rabbit aorta was demonstrated (Fig. 1) . Similar inhibition was found on 2 subsequent occasions during the next 3 months.
Case 2. A 39-year-old woman with a 15-year history of SLE recently developed renal involvement with proteinuria and a reduced creatinine clearance rate. Two months before this she had an anterolateral myocardial infarction. At the time of study she was in complete remission, with normal plasma DNA binding activity and immune complex levels and was taking prednisone 10 mg daily and azathioprine 125 tg daily. Inhibition of PGI2 activity (similar to that of patient 1) was demonstrated. This was confirmed on a subsequent examination, but at present PGI2 activity is normal. 
Discussion
Prostacyclin is produced by vascular tissue and is a potent vasodilator and inhibitor of platelet aggregation. It has been demonstrated that PGI2f prevents platelets adhering to normal vascular endothelial surfaces4 in an in-vitro system. The role of PGI2 in the prevention of arterial and venous thrombotic disease is at present unknown. It had been suggested that diseases such as thrombotic thrombocytopenic purpura lack PGI2 owing to a deficiency of a necessary plasma factor.6 PGI2 has been shown to significantly improve the symptoms of patients with severe, advanced peripheral vascular disease possibly owing to its ability to disperse platelet aggregates.7
It is therefore likely that any disease which inhibits the formation of PGI2 or alters the activity of released PGI2 renders a patient more susceptible to thrombotic episodes. The plasma from 2 of our 24 patients with SLE clearly impaired the activity of PGI2 obtained from rabbit aorta. Furthermore, these were the only patients in this study group to have a previous history of thrombotic episodes. While a cause-and-effect relationship cannot be determined on such a small number of patients, the finding is nevertheless interesting and worthy of further study.
While inhibitory activity is no longer detectable in both patients' plasma, it must be recognised that our test system is crude and lacks sensitivity. More sensitive test systems may demonstrate a higher incidence of absent plasma PGI2 activity in this group of patients. systemic lupus erythematosus. 
Reduced prostacyclin activity in

